The X-TOLE2 clinical trial now underway to examine XEN1101 administered as an adjunctive treatment for adult patients with focal onset seizures
Download BrochureWe hope you can visit our scientific exhibit taking place on Sunday, Dec. 4th from 2-5 pm in Room 207 C on Level 2 of the Music City Center. Or, stop by Xenon's booth #1028 to learn more about our novel product pipeline.
Let us know if you would like to learn more about Xenon's XEN1101 Phase 3 program, including our X-TOLE2, X-TOLE3, and X-ACKT clinical trials, by emailing us at medicalaffairs@xenon-pharma.com.